MX2018001193A - Compuestos de derivados de 1,3,4-oxadiazolsulfonamida como inhibidor de histona desacetilasa 6, y la composición farmacéutica que comprende los mismos. - Google Patents
Compuestos de derivados de 1,3,4-oxadiazolsulfonamida como inhibidor de histona desacetilasa 6, y la composición farmacéutica que comprende los mismos.Info
- Publication number
- MX2018001193A MX2018001193A MX2018001193A MX2018001193A MX2018001193A MX 2018001193 A MX2018001193 A MX 2018001193A MX 2018001193 A MX2018001193 A MX 2018001193A MX 2018001193 A MX2018001193 A MX 2018001193A MX 2018001193 A MX2018001193 A MX 2018001193A
- Authority
- MX
- Mexico
- Prior art keywords
- histone deacetylase
- same
- inhibitor
- pharmaceutical composition
- derivative compounds
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- -1 1,3,4-oxadiazole sulfonamide derivative compounds Chemical class 0.000 title 1
- 229940122617 Histone deacetylase 6 inhibitor Drugs 0.000 title 1
- 102000003964 Histone deacetylase Human genes 0.000 abstract 5
- 108090000353 Histone deacetylase Proteins 0.000 abstract 5
- 150000001875 compounds Chemical class 0.000 abstract 3
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 230000002401 inhibitory effect Effects 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 230000001404 mediated effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 229940126585 therapeutic drug Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
La presente invención se refiere a compuestos novedosos representados por la fórmula I que tienen actividad inhibidora de histona desacetilasa (HDAC6), estereoisómeros de los mismos o sales farmacéuticamente aceptables de los mismos, el uso de los mismos para la preparación de medicamentos terapéuticos, composiciones farmacéuticas que contienen los mismos, un método de tratamiento de enfermedades usando la composición, y métodos de preparación de los compuestos novedosos (I). Los compuestos novedosos, estereoisómeros de los mismos o sales farmacéuticamente aceptables de los mismos según la presente invención tienen actividad inhibidora de histona desacetilasa (HDAC) y son eficaces para la prevención o el tratamiento de enfermedades mediadas por HDAC6.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20150105976 | 2015-07-27 | ||
| PCT/KR2016/008214 WO2017018803A1 (en) | 2015-07-27 | 2016-07-27 | 1,3,4-oxadiazole sulfonamide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2018001193A true MX2018001193A (es) | 2018-05-22 |
| MX376584B MX376584B (es) | 2025-03-07 |
Family
ID=57886873
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018001193A MX376584B (es) | 2015-07-27 | 2016-07-27 | Compuestos de derivados de 1,3,4-oxadiazolsulfonamida como inhibidor de histona desacetilasa 6, y la composición farmacéutica que comprende los mismos |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US10538498B2 (es) |
| EP (1) | EP3328843B1 (es) |
| JP (1) | JP6560436B2 (es) |
| KR (1) | KR101799007B1 (es) |
| CN (1) | CN107922362B (es) |
| AU (1) | AU2016299484B2 (es) |
| CA (1) | CA2993929C (es) |
| DK (1) | DK3328843T3 (es) |
| ES (1) | ES2935932T3 (es) |
| FI (1) | FI3328843T3 (es) |
| HR (1) | HRP20230052T1 (es) |
| HU (1) | HUE061174T2 (es) |
| MX (1) | MX376584B (es) |
| MY (1) | MY197262A (es) |
| NZ (1) | NZ739026A (es) |
| PH (1) | PH12018500212A1 (es) |
| PL (1) | PL3328843T3 (es) |
| PT (1) | PT3328843T (es) |
| RU (1) | RU2697665C1 (es) |
| TW (1) | TWI639587B (es) |
| WO (1) | WO2017018803A1 (es) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3291809B1 (en) | 2015-05-07 | 2021-08-25 | CHDI Foundation, Inc. | Histone deacetylase inhibitors and compositions and methods of use thereof |
| US10053434B2 (en) | 2015-05-07 | 2018-08-21 | Chdi Foundation, Inc. | Histone deacetylase inhibitors and compositions and methods of use thereof |
| ES2935932T3 (es) | 2015-07-27 | 2023-03-13 | Chong Kun Dang Pharmaceutical Corp | Compuestos de derivados de 1,3,4-oxadiazolsulfonamida como inhibidor de histona desacetilasa 6, y la composición farmacéutica que comprende los mismos |
| AU2016299485B2 (en) | 2015-07-27 | 2019-02-07 | Chong Kun Dang Pharmaceutical Corp. | 1,3,4-oxadiazole amide derivative compound as histone deacetylase 6 inhibitor, and pharmaceutical composition containing same |
| MX376585B (es) * | 2015-07-27 | 2025-03-07 | Chong Kun Dang Pharmaceutical Corp | Compuestos derivados de sulfamida de 1,3,4-oxadiazol como inhibidor de histona desacetilasa 6, y la composición farmacéutica que comprende los mismos. |
| AU2016303891B2 (en) | 2015-08-04 | 2019-08-01 | Chong Kun Dang Pharmaceutical Corp. | 1,3,4-oxadiazole derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same |
| HUE061967T2 (hu) * | 2015-10-12 | 2023-09-28 | Chong Kun Dang Pharmaceutical Corp | Hiszton deacetiláz-6 inhibitor oxadiazol-amin származékok és az azokat tartalmazó gyógyászati készítmény |
| WO2018153730A1 (en) * | 2017-02-21 | 2018-08-30 | Basf Se | Substituted oxadiazoles for combating phytopathogenic fungi |
| WO2018165520A1 (en) | 2017-03-10 | 2018-09-13 | Vps-3, Inc. | Metalloenzyme inhibitor compounds |
| US20210101874A1 (en) * | 2017-04-03 | 2021-04-08 | Syngenta Participations Ag | Microbiocidal oxadiazole derivatives |
| WO2019027054A1 (en) | 2017-07-31 | 2019-02-07 | Takeda Pharmaceutical Company Limited | HETEROCYCLIC COMPOUND |
| US11261201B2 (en) | 2018-01-12 | 2022-03-01 | President And Fellows Of Harvard College | TRNA synthetase inhibitors |
| WO2019140254A1 (en) * | 2018-01-12 | 2019-07-18 | President And Fellows Of Harvard College | Multicyclic compounds and use of same for treating tuberculosis |
| KR102316234B1 (ko) | 2018-07-26 | 2021-10-22 | 주식회사 종근당 | 히스톤 탈아세틸화효소 6 억제제로서의 1,3,4-옥사다이아졸 유도체 화합물 및 이를 포함하는 약제학적 조성물 |
| EP3883572A4 (en) * | 2018-11-23 | 2022-11-30 | Chong Kun Dang Pharmaceutical Corp. | PHARMACEUTICAL COMPOSITION WITH HISTONE DEACETYLASE-6 INHIBITORS |
| US12084436B2 (en) | 2019-01-30 | 2024-09-10 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| JP7593647B2 (ja) * | 2019-04-17 | 2024-12-03 | キマトリクス、エセ．エレ． | ヒストン脱アセチル化酵素阻害剤としての１，３，４－オキサジアゾール誘導体 |
| PH12021552905A1 (en) | 2019-05-31 | 2022-04-04 | Chong Kun Dang Pharmaceutical Corp | 1,3,4-oxadiazole homophthalimide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same |
| US12485174B2 (en) | 2019-06-27 | 2025-12-02 | The George Washington University, A Congressionally Chartered Not-For-Profit Corporation | HDAC6-activated macrophages, compositions, and uses thereof |
| CN114846012B (zh) | 2019-09-27 | 2024-01-26 | 武田药品工业株式会社 | 可用作hdac6抑制剂的2-异吲哚-1,3,4-噁二唑衍生物 |
| BR112022011917A2 (pt) | 2019-12-20 | 2022-09-06 | Tenaya Therapeutics Inc | Fluoroalquil-oxadiazois e seus usos |
| KR102537616B1 (ko) | 2020-02-25 | 2023-05-26 | 주식회사 종근당 | 히스톤 탈아세틸화 효소 6 억제제로서의 1,3,4-옥사다이아졸 유도체 화합물 및 이를 포함하는 약제학적 조성물 |
| KR102576148B1 (ko) * | 2020-04-13 | 2023-09-07 | 주식회사 종근당 | 히스톤 탈아세틸화효소 6 억제제로서의 1,3,4-옥사다이아졸 유도체 화합물 및 이를 포함하는 약제학적 조성물 |
| CA3189738A1 (en) | 2020-08-07 | 2022-02-10 | Italfarmaco S.P.A. | Novel oxadiazole-based selective hdac6 inhibitors |
| US20240148744A1 (en) * | 2021-02-09 | 2024-05-09 | Celgene Corporation | Sulfonamides and their use for treatment of helminthic infections and diseases |
| US20240208956A1 (en) * | 2021-04-08 | 2024-06-27 | Chong Kun Dang Pharmaceutical Corp. | 1,3,4-oxadiazole thiocarbonyl compounds as histone deacetylase 6 inhibitor, and pharmaceutical composition comprising the same |
| EP4326263A1 (en) | 2021-04-23 | 2024-02-28 | Tenaya Therapeutics, Inc. | Hdac6 inhibitors for use in the treatment of dilated cardiomyopathy |
| MX2023012875A (es) | 2021-05-04 | 2024-01-12 | Tenaya Therapeutics Inc | Inhibidores 2-fluoro alquil-l,3,4-oxadiazol-5-il-tiazol de hdac6 para su uso en el tratamiento de enfermedades metabólicas y hfpef. |
| CN114181187A (zh) * | 2021-11-24 | 2022-03-15 | 上海应用技术大学 | 一种4-甲磺酰胺基丁酰胺化合物的制备方法 |
| TW202337446A (zh) * | 2022-01-28 | 2023-10-01 | 韓商鐘根堂股份有限公司 | 用於預防或治療肺動脈高血壓之組合物 |
| JP2025512815A (ja) * | 2022-04-07 | 2025-04-22 | チョン クン ダン ファーマシューティカル コーポレイション | ヒストン脱アセチル化酵素６阻害剤としての１，３，４－オキサジアゾール誘導体化合物およびその用途 |
| KR20240035172A (ko) * | 2022-09-08 | 2024-03-15 | 주식회사 종근당 | 히스톤 탈아세틸화효소 6 억제제로서의 1,3,4-옥사다이아졸 유도체 화합물 및 이의 용도 |
| WO2024079682A1 (en) * | 2022-10-14 | 2024-04-18 | Chong Kun Dang Pharmaceutical Corp. | Sulfoximine compounds as histone deacetylase 6 inhibitor, and pharmaceutical composition comprising the same |
| WO2025215092A1 (en) | 2024-04-10 | 2025-10-16 | Institut National de la Santé et de la Recherche Médicale | Selective hdac6 inhibitors for use in the treatment of myotonic dystrophy type 1 |
Family Cites Families (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0276432A3 (de) | 1986-12-12 | 1988-10-26 | Ciba-Geigy Ag | Schädlingsbekämpfungsmittel |
| KR100265385B1 (ko) | 1998-02-27 | 2000-11-01 | 윤여표 | 순환기 질환의 예방 및 치료 효능을 갖는 홍경천 추출물 |
| US6897220B2 (en) | 2001-09-14 | 2005-05-24 | Methylgene, Inc. | Inhibitors of histone deacetylase |
| US7868204B2 (en) | 2001-09-14 | 2011-01-11 | Methylgene Inc. | Inhibitors of histone deacetylase |
| JP2005509606A (ja) | 2001-10-03 | 2005-04-14 | ファルマシア・コーポレーション | 凝血カスケードを選択的に阻害するのに有用な置換された多環式化合物のプロドラッグ |
| HUP0500173A3 (en) | 2001-12-20 | 2009-03-30 | Bristol Myers Squibb Co | Alpha-sulphonamido-acetamide derivatives as beta-amyloid inhibitors and pharmaceutical compositions containing them |
| AU2006270322A1 (en) * | 2005-07-14 | 2007-01-25 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
| US20070037865A1 (en) | 2005-08-04 | 2007-02-15 | Sirtris Pharmaceuticals, Inc. | Sirtuin modulating compounds |
| WO2007032445A1 (ja) | 2005-09-16 | 2007-03-22 | Kyowa Hakko Kogyo Co., Ltd. | タンパク質キナーゼ阻害剤 |
| GB0603041D0 (en) * | 2006-02-15 | 2006-03-29 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
| KR20090017483A (ko) | 2006-03-23 | 2009-02-18 | 프롤리시스 리미티드 | 항균제 |
| WO2007143822A1 (en) | 2006-06-14 | 2007-12-21 | Methylgene Inc. | Sulfamide and sulfamate derivatives as histone deacetylase inhibitors |
| EP1878730A1 (en) | 2006-07-12 | 2008-01-16 | Bayer Schering Pharma Aktiengesellschaft | Substituted isoxazolines, pharmaceutical compositions containing the same, methods of preparing the same, and uses of the same |
| SI2099489T1 (sl) | 2006-12-11 | 2014-09-30 | Genentech, Inc. | Sestavki in postopki za zdravljenje neoplazme |
| WO2009010479A2 (en) | 2007-07-13 | 2009-01-22 | Euroscreen S.A. | Heterocyclic methylene piperidine derivatives and their use |
| KR100903743B1 (ko) | 2007-08-28 | 2009-06-19 | 전병태 | 소화기계 질환개선 및 예방용 식품 조성물 |
| WO2009059283A1 (en) | 2007-11-02 | 2009-05-07 | Momenta Pharmaceuticals, Inc. | Non-anticoagulant polysaccharide compositions |
| WO2009055917A1 (en) | 2007-11-02 | 2009-05-07 | Methylgene Inc. | Inhibitors of histone deacetylase |
| KR101708946B1 (ko) | 2008-07-23 | 2017-02-21 | 다나-파버 캔서 인스티튜트 인크. | 탈아세틸화제 억제제 및 그것의 용도 |
| WO2010123933A1 (en) * | 2009-04-20 | 2010-10-28 | Institute For Oneworld Health | Compounds, compositions and methods comprising 1,3,4-oxadiazole derivatives |
| WO2010126002A1 (ja) | 2009-04-28 | 2010-11-04 | 塩野義製薬株式会社 | ヘテロ環スルホンアミド化合物を含有する医薬 |
| JP2011008205A (ja) | 2009-05-27 | 2011-01-13 | Fujifilm Corp | 二軸性光学異方性膜を作製するための組成物 |
| US8431538B2 (en) | 2009-07-22 | 2013-04-30 | The Board Of Trustees Of The University Of Illinois | HDAC inhibitors and therapeutic methods of using same |
| KR101781663B1 (ko) | 2010-01-13 | 2017-09-25 | 템페로 파마슈티칼즈, 인크. | 히스톤 데아세틸라제 효소를 억제하기 위한 화합물 및 이를 제조하는 방법 |
| US8981084B2 (en) | 2010-01-13 | 2015-03-17 | Tempero Pharmaceuticals, Inc. | Oxadiazole HDAC inhibitors |
| CN102933558B (zh) | 2010-01-22 | 2016-03-16 | 埃斯泰隆制药公司 | 作为蛋白质去乙酰化酶抑制剂的反向酰胺化合物及其使用方法 |
| TW201141854A (en) | 2010-02-25 | 2011-12-01 | Piramal Lifesciences Ltd | Oxadiazole compounds, their preparation and use |
| AR081331A1 (es) | 2010-04-23 | 2012-08-08 | Cytokinetics Inc | Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos |
| NZ603477A (en) | 2010-05-12 | 2014-09-26 | Vertex Pharma | Compounds useful as inhibitors of atr kinase |
| US8697739B2 (en) * | 2010-07-29 | 2014-04-15 | Novartis Ag | Bicyclic acetyl-CoA carboxylase inhibitors and uses thereof |
| JP5851516B2 (ja) | 2010-12-09 | 2016-02-03 | ウォックハート リミテッド | ケトライド化合物 |
| KR101262870B1 (ko) | 2011-01-28 | 2013-05-09 | 환인제약 주식회사 | 호장근 추출물을 함유하는 호흡기 질환의 예방 또는 치료용 조성물 |
| US9056843B2 (en) | 2011-07-08 | 2015-06-16 | Novartis Ag | Trifluoromethyl-oxadiazole derivatives and their use in the treatment of disease |
| WO2013013113A2 (en) | 2011-07-20 | 2013-01-24 | The General Hospital Corporation | Histone deacetylase 6 selective inhibitors for the treatment of bone disease |
| WO2013041407A1 (en) | 2011-09-19 | 2013-03-28 | Cellzome Ag | Hydroxamic acids as hdac6 inhibitors |
| EP2763531A4 (en) | 2011-10-03 | 2015-11-18 | Univ Columbia | NEW MOLECULES FOR THE SELECTIVE INHIBITION OF HISTONDEACETYLASE 6 IN RELATION TO HISTONDEACETYLASE 1 |
| WO2013066835A2 (en) | 2011-10-31 | 2013-05-10 | Glaxosmithkline Llc | Compounds and methods |
| WO2013066839A2 (en) | 2011-10-31 | 2013-05-10 | Glaxosmithkline Llc | Compounds and methods |
| WO2013066838A1 (en) | 2011-10-31 | 2013-05-10 | Glaxosmithkline Llc | Compounds and methods |
| WO2013066833A1 (en) | 2011-10-31 | 2013-05-10 | Glaxosmithkline Llc | Compounds and methods to inhibit histone deacetylase (hdac) enzymes |
| ES2606630T3 (es) | 2011-11-28 | 2017-03-24 | Novartis Ag | Derivados de trifluorometil-oxadiazol novedosos y su uso en el tratamiento de enfermedad |
| JP6272773B2 (ja) | 2011-11-29 | 2018-01-31 | ナンジン アルゲン ファルマ カンパニー リミテッドＮａｎｊｉｎｇ Ａｌｌｇｅｎ Ｐｈａｒｍａ Ｃｏ． Ｌｔｄ． | Ｈｄａｃ６阻害剤・抗腫瘍剤用複素環アミド化合物 |
| JP6233812B2 (ja) | 2012-03-07 | 2017-11-22 | エイチ リー モフィット キャンサー センター アンド リサーチ インスティテュート インコーポレイテッド | 選択的ヒストンデアセチラーゼ６阻害剤 |
| SG11201601679TA (en) | 2013-09-06 | 2016-04-28 | Aurigene Discovery Tech Ltd | 1,3,4-oxadiazole and 1,3,4-thiadiazole derivatives as immunomodulators |
| PL3080125T3 (pl) | 2013-12-12 | 2019-06-28 | Chong Kun Dang Pharmaceutical Corp. | Pochodne azaindolu jako selektywne inhibitory deacetylazy histonowej (HDAC) i zawierające je kompozycje farmaceutyczne |
| CN104744446B (zh) | 2013-12-30 | 2019-06-25 | 广东东阳光药业有限公司 | 杂芳化合物及其在药物中的应用 |
| CN107108593B (zh) | 2014-11-24 | 2020-03-24 | 美迪福伦Dbt有限公司 | 作为类香草素受体配体ii的基于取代的恶唑和噻唑的羧酰胺和脲衍生物 |
| CN106349451B (zh) | 2015-07-14 | 2020-11-13 | 罗门哈斯公司 | 用于制备疏水改性环氧烷氨基甲酸酯聚合物的方法 |
| AU2016299485B2 (en) | 2015-07-27 | 2019-02-07 | Chong Kun Dang Pharmaceutical Corp. | 1,3,4-oxadiazole amide derivative compound as histone deacetylase 6 inhibitor, and pharmaceutical composition containing same |
| MX376585B (es) | 2015-07-27 | 2025-03-07 | Chong Kun Dang Pharmaceutical Corp | Compuestos derivados de sulfamida de 1,3,4-oxadiazol como inhibidor de histona desacetilasa 6, y la composición farmacéutica que comprende los mismos. |
| ES2935932T3 (es) | 2015-07-27 | 2023-03-13 | Chong Kun Dang Pharmaceutical Corp | Compuestos de derivados de 1,3,4-oxadiazolsulfonamida como inhibidor de histona desacetilasa 6, y la composición farmacéutica que comprende los mismos |
| AU2016303891B2 (en) | 2015-08-04 | 2019-08-01 | Chong Kun Dang Pharmaceutical Corp. | 1,3,4-oxadiazole derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same |
| HUE061967T2 (hu) | 2015-10-12 | 2023-09-28 | Chong Kun Dang Pharmaceutical Corp | Hiszton deacetiláz-6 inhibitor oxadiazol-amin származékok és az azokat tartalmazó gyógyászati készítmény |
-
2016
- 2016-07-27 ES ES16830836T patent/ES2935932T3/es active Active
- 2016-07-27 RU RU2018106877A patent/RU2697665C1/ru active
- 2016-07-27 NZ NZ739026A patent/NZ739026A/en unknown
- 2016-07-27 MY MYPI2018700258A patent/MY197262A/en unknown
- 2016-07-27 DK DK16830836.9T patent/DK3328843T3/da active
- 2016-07-27 KR KR1020160095332A patent/KR101799007B1/ko active Active
- 2016-07-27 WO PCT/KR2016/008214 patent/WO2017018803A1/en not_active Ceased
- 2016-07-27 MX MX2018001193A patent/MX376584B/es active IP Right Grant
- 2016-07-27 HR HRP20230052TT patent/HRP20230052T1/hr unknown
- 2016-07-27 CN CN201680044430.0A patent/CN107922362B/zh active Active
- 2016-07-27 CA CA2993929A patent/CA2993929C/en active Active
- 2016-07-27 FI FIEP16830836.9T patent/FI3328843T3/fi active
- 2016-07-27 AU AU2016299484A patent/AU2016299484B2/en active Active
- 2016-07-27 PT PT168308369T patent/PT3328843T/pt unknown
- 2016-07-27 HU HUE16830836A patent/HUE061174T2/hu unknown
- 2016-07-27 US US15/747,952 patent/US10538498B2/en active Active
- 2016-07-27 TW TW105123824A patent/TWI639587B/zh active
- 2016-07-27 PL PL16830836.9T patent/PL3328843T3/pl unknown
- 2016-07-27 JP JP2018503804A patent/JP6560436B2/ja active Active
- 2016-07-27 EP EP16830836.9A patent/EP3328843B1/en active Active
-
2018
- 2018-01-26 PH PH12018500212A patent/PH12018500212A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ES2935932T3 (es) | 2023-03-13 |
| MY197262A (en) | 2023-06-08 |
| TW201712001A (zh) | 2017-04-01 |
| EP3328843B1 (en) | 2022-10-26 |
| EP3328843A1 (en) | 2018-06-06 |
| WO2017018803A1 (en) | 2017-02-02 |
| CN107922362B (zh) | 2021-06-15 |
| BR112018001720A2 (pt) | 2018-11-06 |
| AU2016299484A1 (en) | 2018-02-01 |
| TWI639587B (zh) | 2018-11-01 |
| JP6560436B2 (ja) | 2019-08-14 |
| RU2697665C1 (ru) | 2019-08-16 |
| JP2018526343A (ja) | 2018-09-13 |
| PT3328843T (pt) | 2023-01-24 |
| FI3328843T3 (fi) | 2023-01-31 |
| HUE061174T2 (hu) | 2023-05-28 |
| DK3328843T3 (da) | 2023-01-09 |
| PH12018500212A1 (en) | 2018-08-13 |
| CN107922362A (zh) | 2018-04-17 |
| HK1251571A1 (zh) | 2019-02-01 |
| KR20170013836A (ko) | 2017-02-07 |
| NZ739026A (en) | 2019-03-29 |
| HRP20230052T1 (hr) | 2023-03-03 |
| US10538498B2 (en) | 2020-01-21 |
| US20180251437A1 (en) | 2018-09-06 |
| CA2993929A1 (en) | 2017-02-02 |
| EP3328843A4 (en) | 2019-01-16 |
| PL3328843T3 (pl) | 2023-02-27 |
| CA2993929C (en) | 2020-10-20 |
| AU2016299484B2 (en) | 2019-08-01 |
| MX376584B (es) | 2025-03-07 |
| KR101799007B1 (ko) | 2017-11-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2018001193A (es) | Compuestos de derivados de 1,3,4-oxadiazolsulfonamida como inhibidor de histona desacetilasa 6, y la composición farmacéutica que comprende los mismos. | |
| MX2018001487A (es) | Compuestos derivados de 1,3,4-oxadiazol como inhibidores de histona desacetilasa 6 y la composición farmacéutica que comprende los mismos. | |
| MX2018001196A (es) | Compuesto derivado de amida de 1,3,4-oxadiazol como inhibidor de histona desacetilasa 6 y composición farmacéutica que lo contiene. | |
| CY1123810T1 (el) | Τριφθορομεθυλ υποκατεστημενα πυραζολια ως αναστολεις καλλικρεϊνης στο ανθρωπινο πλασμα | |
| MX2017017090A (es) | Compuestos derivados de sulfamida de 1,3,4-oxadiazol como inhibidor de histona desacetilasa 6, y la composicion farmaceutica que comprende los mismos. | |
| MX2018004447A (es) | Compuestos derivados de oxadiazolamina como inhibidores de histona desacetilasa 6, y la composición farmacéutica que comprende los mismos. | |
| MX2015008396A (es) | Derivados de la 2,3-dihidro-isoindol-1-ona, como inhibidores de la btk quinasa y composiciones farmacéuticas que los incluyen. | |
| CO2018005640A2 (es) | Compuestos inhibidores de jak quinasa para el tratamiento de enfermedad respiratoria | |
| TR201816176T4 (tr) | Histon deasetilaz 6 inhibitörleri olarak yeni bileşikler ve bunu içeren farmasötik bileşimler. | |
| CL2019002745A1 (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue. | |
| CL2019003309A1 (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue. | |
| CL2019002744A1 (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue. | |
| BR112016028876A2 (pt) | composto, composição farmacêutica, método para tratar uma doença ou condição em um ser humano, kit, e, uso de um composto, um sal, isômero ou uma mistura farmaceuticamente aceitável dos mesmos. | |
| CL2019003294A1 (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue. | |
| UY37837A (es) | Nuevos compuestos heterocíclicos como inhibidores de cdk8/19 | |
| UY36124A (es) | Derivados de carboxamida | |
| EA202191548A1 (ru) | Ингибиторы плазменного калликреина человека | |
| UY36123A (es) | Derivados de carboxamida | |
| MX2017014953A (es) | Compuestos derivados de alquilos heterociclicos como inhibidores de histona desacetilasa selectivos y composiciones farmaceuticas que los comprenden. | |
| UY37745A (es) | Compuestos bicíclicos 5,6 fusionados y composiciones para el tratamiento de las enfermedades parasitarias | |
| CL2017002229A1 (es) | Inhibidores de bace1. | |
| BR112018003313A2 (pt) | novo derivado de catecol e composição farmacêutica compreendendo o mesmo | |
| MX386902B (es) | Metodos para el tratamiento de trastornos cardiovasculares. | |
| EA201992005A1 (ru) | Арильные, гетероарильные и гетероциклические фармацевтические соединения для лечения медицинских нарушений | |
| CU20160170A7 (es) | Derivados de carboxamida |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |